Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Osada

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Chemistry & Biology|September 17, 2013
Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cellsJared J Barrott, Philip F Hughes, Takuya Osada, et al.
International Journal of Cancer|October 27, 2009
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivoMichael A Morse, Junping Wei, Zachary Hartman, et al.
ACS Chemical Biology|January 20, 2017
A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in VivoLauren B Crowe, Philip F Hughes, David A Alcorta, et al.
Molecular Cancer Therapeutics|June 16, 2011
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitorsWenle Xia, Zuguo Liu, Rongrong Zong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicityZachary C Hartman, Junping Wei, Takuya Osada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2019
Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational StudyErika J Crosby, William Gwin, Kimberly Blackwell, et al.
Plos One|October 11, 2012
Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model systemNicholas C D'Amato, Julie H Ostrander, Michelle L Bowie, et al.
Cancer Immunology, Immunotherapy : CII|April 30, 2013
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patientsMichael A Morse, Arvind Chaudhry, Elizabeth S Gabitzsch, et al.
Plos One|September 2, 2016
X-Ray Psoralen Activated Cancer Therapy (X-PACT)Mark Oldham, Paul Yoon, Zak Fathi, et al.
Molecular Cancer Therapeutics|October 22, 2021
HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I StudyTakuya Osada, Erika J Crosby, Kensuke Kaneko, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Chemistry & Biology|September 17, 2013
Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cellsJared J Barrott, Philip F Hughes, Takuya Osada, et al.
International Journal of Cancer|October 27, 2009
Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivoMichael A Morse, Junping Wei, Zachary Hartman, et al.
ACS Chemical Biology|January 20, 2017
A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in VivoLauren B Crowe, Philip F Hughes, David A Alcorta, et al.
Molecular Cancer Therapeutics|June 16, 2011
Truncated ErbB2 expressed in tumor cell nuclei contributes to acquired therapeutic resistance to ErbB2 kinase inhibitorsWenle Xia, Zuguo Liu, Rongrong Zong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
An adenoviral vaccine encoding full-length inactivated human Her2 exhibits potent immunogenicty and enhanced therapeutic efficacy without oncogenicityZachary C Hartman, Junping Wei, Takuya Osada, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2019
Vaccine-Induced Memory CD8<sup>+</sup> T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational StudyErika J Crosby, William Gwin, Kimberly Blackwell, et al.
Plos One|October 11, 2012
Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model systemNicholas C D'Amato, Julie H Ostrander, Michelle L Bowie, et al.
Cancer Immunology, Immunotherapy : CII|April 30, 2013
Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patientsMichael A Morse, Arvind Chaudhry, Elizabeth S Gabitzsch, et al.
Plos One|September 2, 2016
X-Ray Psoralen Activated Cancer Therapy (X-PACT)Mark Oldham, Paul Yoon, Zak Fathi, et al.
Molecular Cancer Therapeutics|October 22, 2021
HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I StudyTakuya Osada, Erika J Crosby, Kensuke Kaneko, et al.
Pageof 14